Sengenics is a functional proteomics company that leverages its patented KREX protein folding technology to discover autoantibody biomarker signature for drug response prediction, patient stratification and development of companion diagnostics. Our technology ensure that all microarray proteins are full length, correctly folded and functional, enabling specific and quantitative antibody binding to conformational epitopes. The company has a global footprint with multiple corporate and research sites across the world with customers and collaborators that include top pharma, biotech and ivy league academic institutions in North America, Europe, and Asia.